| 1. |
|
|
| 2. |
- Edman, Anne-Christine, 1946-
(author)
-
Myofibrillens finstruktur i tvärstrimmig skelettmuskulatur
- 1988
-
Doctoral thesis (other academic/artistic)abstract
- The detailed structure of the myofibrillar material in fibres from different muscles has been studied. Specimens have been obtained from human muscles and from different muscles frequently examined in experimental studies. Both light- and electron microscopical techniques have been used. Of central importance has been the method, which makes it possible to prepare ultrathin sections of frozen tissue, i.e. cryo-ult- ramicrotomy. A number of techniques for image analysis have been applied in order to obtain objektive data from the micrographs.In Paper I the present knowledge about muscle fibre structure, cryo-- sectioning and image analysis is summarized and relevant methodological problems are discussed. Paper II describes the detailed structure of the C-zone of the A-band and shows, above all, that structures occur with different repeats along the long axis of the myofibril. Paper III describes the subcellular organization of different fibres in a homogeneous (based on enzyme histochemical mATPase) population, and shows that different structural characteristies can vary independently of each other. Paper IV describes the structural diversity of the myofibrillar M-band, and paper V the diversity of the myofilament fine structure in different fibres. The results show that there is a most sophisticated, and previosly unrealized, structural specialization both within the myofibrils and between myofibrils from different fibres and muscles, even if the fibres are of the same fibre type. The findings suggest that generally used models, showing the structural organization within myofibrils and myofilaments, are oversimplifications. The fibre population is more heterogeneously built up than the common systems for fibre type classification makes one to belive.
|
|
| 3. |
- Edman, Anne-Christine, et al.
(author)
-
Structural diversity in muscle fibres of chicken breast
- 1988
-
In: Cell and Tissue Research. - 0302-766X .- 1432-0878. ; 251:2, s. 281-289
-
Journal article (peer-reviewed)abstract
- hicken breast muscle is usually considered to be a relatively homogeneous white muscle and has therefore been widely used for studies of muscle proteins. In a previous study, however, we have found different M-region structures in different fibres from this muscle. Because of this result, we have now carried out a combined histochemical and ultrastructural survey of this muscle. In particular, we have made use of large transverse cryo-sections that include most of the muscle cross-section. Although the white region is fairly homogeneous in fibre content according to normal histochemical criteria (mATPase), we have found that there is a gradation of fibre structure across the muscle. The bulk of the muscle stains conventionally for Type-II fibres according to mATPase tests (the "white" part) but, in the small "red" part of the muscle, there are also Type-I fibres together with the Type-II fibres. Superimposed on this division into Type-I and Type-II fibres are variations in fibre size, oxidative and glycolytic staining properties, and variations of Z-band width and M-band structure; there is no strict correlation among any of these parameters. The apparently uniform staining across most of the muscle when tested for myofibrillar ATPase may be a misleading indicator of fibre properties.
|
|
| 4. |
- Hagell, Peter, et al.
(author)
-
Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson's disease
- 2020
-
In: Journal of Neurology. - 0340-5354 .- 1432-1459. ; 267:11, s. 3411-3417
-
Journal article (peer-reviewed)abstract
- Continuous subcutaneous (s.c.) apomorphine infusion is an effective therapy for Parkinson's disease (PD), but a limitation is the formation of troublesome s.c. nodules. Various chemically non-identical apomorphine formulations are available. Anecdotal experiences have suggested that shifting from one of these (Apo-Go PumpFill®; apoGPF) to another (Apomorphine PharmSwed®; apoPS) may influence the occurrence and severity of s.c. nodules. We, therefore, followed 15 people with advanced PD (median PD-duration, 15 years; median "off"-phase Hoehn and Yahr, IV) on apoGPF and with troublesome s.c. nodules who were switched to apoPS. Data were collected at baseline, at the time of switching, and at a median of 1, 2.5, and 7.3 months post-switch. Total nodule numbers (P < 0.001), size (P < 0.001), consistency (P < 0.001), skin changes (P = 0.058), and pain (P ≤ 0.032) improved over the observation period. PD severity and dyskinesias tended to improve and increase, respectively. Apomorphine doses were stable, but levodopa doses increased by 100 mg/day. Patient-reported apomorphine efficacy tended to increase and all participants remained on apoPS throughout the observation period; with the main patient-reported reason being improved nodules. These observations suggest that patients with s.c. nodules caused by apoGPF may benefit from switching to apoPS in terms of s.c. nodule occurrence and severity. Alternatively, observed benefits may have been due to the switch itself. As nodule formation is a limiting factor in apomorphine treatment, a controlled prospective study comparing local tolerance with different formulations is warranted.
|
|
| 5. |
- Hagell, Peter, et al.
(author)
-
Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson's disease
- 2020
-
In: Journal of Neurology. - : D. Steinkopff-Verlag. - 0340-5354 .- 1432-1459. ; 267:11, s. 3411-3417
-
Journal article (peer-reviewed)abstract
- Continuous subcutaneous (s.c.) apomorphine infusion is an effective therapy for Parkinson's disease (PD), but a limitation is the formation of troublesome s.c. nodules. Various chemically non-identical apomorphine formulations are available. Anecdotal experiences have suggested that shifting from one of these (Apo-Go PumpFill®; apoGPF) to another (Apomorphine PharmSwed®; apoPS) may influence the occurrence and severity of s.c. nodules. We, therefore, followed 15 people with advanced PD (median PD-duration, 15 years; median "off"-phase Hoehn and Yahr, IV) on apoGPF and with troublesome s.c. nodules who were switched to apoPS. Data were collected at baseline, at the time of switching, and at a median of 1, 2.5, and 7.3 months post-switch. Total nodule numbers (P < 0.001), size (P < 0.001), consistency (P < 0.001), skin changes (P = 0.058), and pain (P ≤ 0.032) improved over the observation period. PD severity and dyskinesias tended to improve and increase, respectively. Apomorphine doses were stable, but levodopa doses increased by 100 mg/day. Patient-reported apomorphine efficacy tended to increase and all participants remained on apoPS throughout the observation period; with the main patient-reported reason being improved nodules. These observations suggest that patients with s.c. nodules caused by apoGPF may benefit from switching to apoPS in terms of s.c. nodule occurrence and severity. Alternatively, observed benefits may have been due to the switch itself. As nodule formation is a limiting factor in apomorphine treatment, a controlled prospective study comparing local tolerance with different formulations is warranted.
|
|
| 6. |
|
|
